WO2000062790A8 - Soluble tumor necrosis factor receptor treatment of medical disorders - Google Patents

Soluble tumor necrosis factor receptor treatment of medical disorders

Info

Publication number
WO2000062790A8
WO2000062790A8 PCT/US2000/010565 US0010565W WO0062790A8 WO 2000062790 A8 WO2000062790 A8 WO 2000062790A8 US 0010565 W US0010565 W US 0010565W WO 0062790 A8 WO0062790 A8 WO 0062790A8
Authority
WO
WIPO (PCT)
Prior art keywords
medical disorders
necrosis factor
tumor necrosis
factor receptor
soluble tumor
Prior art date
Application number
PCT/US2000/010565
Other languages
French (fr)
Other versions
WO2000062790A2 (en
WO2000062790A3 (en
Inventor
Barbara K Finck
Original Assignee
Immunex Corp
Barbara K Finck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp, Barbara K Finck filed Critical Immunex Corp
Priority to CA2366785A priority Critical patent/CA2366785C/en
Priority to EP00923525A priority patent/EP1171148A2/en
Priority to AU43632/00A priority patent/AU4363200A/en
Publication of WO2000062790A2 publication Critical patent/WO2000062790A2/en
Priority to US09/778,403 priority patent/US20010021380A1/en
Priority to AU2001245336A priority patent/AU2001245336A1/en
Priority to CA002416250A priority patent/CA2416250A1/en
Priority to EP01918237A priority patent/EP1259252A2/en
Priority to PCT/US2001/006037 priority patent/WO2001062272A2/en
Publication of WO2000062790A3 publication Critical patent/WO2000062790A3/en
Publication of WO2000062790A8 publication Critical patent/WO2000062790A8/en
Priority to US10/314,618 priority patent/US20030148955A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The invention pertains to methods for treating medical disorders characterized by elevated levels or abnormal expression of TNFα by administering a TNFα antagonist, such as recombinant TNFR:Fc.
PCT/US2000/010565 1999-04-19 2000-04-19 Soluble tumor necrosis factor receptor treatment of medical disorders WO2000062790A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA2366785A CA2366785C (en) 1999-04-19 2000-04-19 Soluble tumor necrosis factor receptor treatment of medical disorders
EP00923525A EP1171148A2 (en) 1999-04-19 2000-04-19 Soluble tumor necrosis factor receptor treatment of medical desorders
AU43632/00A AU4363200A (en) 1999-04-19 2000-04-19 Soluble tumor necrosis factor receptor treatment of medical desorders
US09/778,403 US20010021380A1 (en) 1999-04-19 2001-02-07 Soluble tumor necrosis factor receptor treatment of medical disorders
PCT/US2001/006037 WO2001062272A2 (en) 2000-02-25 2001-02-22 Soluble tumor necrosis factor receptor and il-4 inhibitor for the treatment of medical disorders
AU2001245336A AU2001245336A1 (en) 2000-02-25 2001-02-22 Soluble tumor necrosis factor receptor treatment of medical disorders
CA002416250A CA2416250A1 (en) 2000-02-25 2001-02-22 Soluble tumor necrosis factor receptor and il-4 inhibitor for the treatment of medical disorders
EP01918237A EP1259252A2 (en) 2000-02-25 2001-02-22 Soluble tumor necrosis factor receptor and il-4 inhibitor for the treatment of medical disorders
US10/314,618 US20030148955A1 (en) 1999-04-19 2002-12-09 Soluble tumor necrosis factor receptor treatment of medical disorders

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US13007499P 1999-04-19 1999-04-19
US60/130,074 1999-04-19
US13432099P 1999-05-14 1999-05-14
US60/134,320 1999-05-14
US14395999P 1999-07-15 1999-07-15
US60/143,959 1999-07-15
US14823499P 1999-08-11 1999-08-11
US60/148,234 1999-08-11
US37382899A 1999-08-13 1999-08-13
US09/373,828 1999-08-13
US16467699P 1999-11-10 1999-11-10
US60/164,676 1999-11-10
US18486400P 2000-02-25 2000-02-25
US60/184,864 2000-02-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US60235100A Continuation-In-Part 1999-04-19 2000-06-23

Publications (3)

Publication Number Publication Date
WO2000062790A2 WO2000062790A2 (en) 2000-10-26
WO2000062790A3 WO2000062790A3 (en) 2001-07-12
WO2000062790A8 true WO2000062790A8 (en) 2001-08-02

Family

ID=27568861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010565 WO2000062790A2 (en) 1999-04-19 2000-04-19 Soluble tumor necrosis factor receptor treatment of medical disorders

Country Status (4)

Country Link
EP (1) EP1171148A2 (en)
AU (1) AU4363200A (en)
CA (1) CA2366785C (en)
WO (1) WO2000062790A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895266B2 (en) 2000-10-06 2014-11-25 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
PT1914244E (en) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Method of modulating the activity of functional immune molecules
MXPA02007683A (en) * 2000-02-10 2002-12-13 American Home Prod Method of treating or inhibiting cellular injury or cell death.
EP1326626B1 (en) * 2000-10-18 2020-04-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
RS20120253A1 (en) 2001-05-24 2013-02-28 Zymogenetics Inc. Taci-immunoglobulin fusion proteins
WO2003009864A1 (en) * 2001-07-23 2003-02-06 Genset S.A. Agonists and antagonists of disomet for the treatment of metabolic disorders
GB0128138D0 (en) * 2001-11-23 2002-01-16 King S College London Pharmaceutical use
EP3210624A1 (en) 2002-02-27 2017-08-30 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
WO2003072060A2 (en) 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
WO2005035586A1 (en) * 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
CN101500607B (en) 2005-05-16 2013-11-27 阿布维生物技术有限公司 Use of TNFalpha inhibitor for treatment of erosive polyarthritis
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc Self-buffering protein formulations
EA016083B1 (en) 2005-08-09 2012-02-28 Займоджинетикс, Инк. Methods for treating b-non-hodgkin's lymphoma using taci-ig fusion molecule
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
WO2007082542A1 (en) * 2006-01-17 2007-07-26 Astion Pharma A/S Compositions comprising oxaprozin and a vitamin d3 analogue and their use for the manufacture of a medicament for the treatment of psoriasis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2007121538A1 (en) * 2006-04-26 2007-11-01 Plasma Ventures Pty Ltd Anti-inflammatory blood product and method of use
MX2008014365A (en) 2006-05-15 2008-11-27 Ares Trading Sa Methods for treating autoimmune diseases using a taci-ig fusion molecule.
ES2759931T3 (en) 2011-04-20 2020-05-12 Sandoz Ag Stable Pharmaceutical Liquid Formulations of Fusion Protein TNFR: Fc
JP6463968B2 (en) 2011-07-01 2019-02-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Tumor necrosis factor receptor without arginine: FC fusion polypeptide composition and methods of use thereof
WO2013059406A1 (en) 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
EP2869817A4 (en) 2012-07-09 2016-04-06 Coherus Biosciences Inc Stable aqueous formulations of etanercept
BR112015005161A2 (en) 2012-09-11 2017-07-04 Coherus Biosciences Inc correctly folded etanercept in high purity and excellent yield
CA2902298A1 (en) 2013-03-06 2014-09-12 Protalix Ltd. Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
EP3268042A4 (en) 2015-03-13 2018-08-01 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
WO2017123672A1 (en) * 2016-01-12 2017-07-20 Lawrence Chan Combination treatment for inflammatory diseases
BR112019007858A2 (en) 2016-10-21 2019-07-02 Amgen Inc pharmaceutical formulations and methods for producing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69724451T2 (en) * 1996-12-06 2004-03-18 Amgen Inc., Thousand Oaks COMBINATION THERAPY WITH A TNF-BINDING PROTEIN FOR TREATING DISEASES CAUSED BY TNF
EP0869179A1 (en) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation Tumor necrosis related receptor, TR7

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895266B2 (en) 2000-10-06 2014-11-25 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US9409982B2 (en) 2000-10-06 2016-08-09 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell

Also Published As

Publication number Publication date
WO2000062790A2 (en) 2000-10-26
CA2366785C (en) 2012-02-07
AU4363200A (en) 2000-11-02
CA2366785A1 (en) 2000-10-26
EP1171148A2 (en) 2002-01-16
WO2000062790A3 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
WO2000062790A8 (en) Soluble tumor necrosis factor receptor treatment of medical disorders
WO2001062272A3 (en) Soluble tumor necrosis factor receptor and il-4 inhibitor for the treatment of medical disorders
WO2002032374A3 (en) Methods for treating il-18 mediated disorders
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
WO2003014309A3 (en) Interleukin-1 receptors in the treatment of diseases
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
IL146482A (en) Tek antagonists
WO2004009784A3 (en) Novel inhibitors of kinases
WO2001001748A3 (en) Peptide compounds that bind her2
WO2002022153A3 (en) Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
WO2005048935A3 (en) Methods of modulating immunity
WO2003013535A3 (en) Use of irinotecan for improved treatment of cancer based on mdr1
WO2004054514A3 (en) C-6 modified indazolylpyrrolotriazines
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2003042172A3 (en) C-5 modified indazolylpyrrolotriazines
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
IL145068A0 (en) The use of glycine betaine to prepare a pharmaceutical composition
WO2004064836A3 (en) Treatment of diseases with alpha-7 nach receptor full agonists
WO2003015713A3 (en) Treatment of glial tumors with glutamate antagonists
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2002020768A3 (en) Caveolin peptides and their use as therapeutics
WO2002094196A3 (en) Method of treatment for cancers associated with elevated
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors
BG104092A (en) Cd154 blockade therapy for the treatment of protein inhibition syndrome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE AND DELETE THE PUBLISHED FIGURE

ENP Entry into the national phase in:

Ref document number: 2366785

Country of ref document: CA

Ref country code: CA

Ref document number: 2366785

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000923525

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 515435

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2000923525

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000923525

Country of ref document: EP